Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
Type:
Application
Filed:
November 18, 2013
Publication date:
March 13, 2014
Applicant:
Rutgers, The State University of New Jersey
Inventors:
Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 13, 2014
Applicant:
Board of Regents of the Nevada System of Higher Education On Behalf of the University of Nevada
Abstract: Soluble granule formulations of amine salts of pyridine containing carboxylic acids with improved handling properties are provided by an improved process in which the pyridine containing carboxylic acid is partially neutralized with an amine.
Type:
Grant
Filed:
November 22, 2010
Date of Patent:
March 11, 2014
Assignee:
Dow AgroSciences, LLC.
Inventors:
Franklin N. Keeney, Neil A. Foster, Martin C. Logan, Maria G. Perry
Abstract: The present disclosure provides methods for identifying therapeutic agents that are multifunctional radical quenchers. It also provides compounds of formula (I), (II), or (II-A): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.
Type:
Application
Filed:
April 4, 2012
Publication date:
February 6, 2014
Inventors:
Sidney Hecht, Omar Khdour, Sandipan Roy Chowdhury, Poulami Talukder
Abstract: A system for the protection against degradation during pelleting of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.
Type:
Application
Filed:
August 2, 2013
Publication date:
February 6, 2014
Applicant:
Kemin Industries, Inc.
Inventors:
Sarah E. Boucher, Jill Davidson, Bill L. Miller
Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
Type:
Grant
Filed:
November 9, 2009
Date of Patent:
February 4, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Eric Mertz, Sung-Sau So, HongYing Yun, Zhenshan Zhang
Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
Type:
Grant
Filed:
February 21, 2012
Date of Patent:
January 28, 2014
Assignee:
Board of Regents, The University of Texas System
Abstract: A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants.
Type:
Application
Filed:
September 19, 2013
Publication date:
January 23, 2014
Applicant:
SYNGENTA PARTICIPATIONS AG
Inventors:
Hans Tobler, Harald Walter, Ulrich Johannes Haas
Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Type:
Grant
Filed:
November 9, 2009
Date of Patent:
December 17, 2013
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, candidiasis (moniliasis), Candida albicans, tinea (pityriasis) vesicolor, Malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.
Abstract: Methods for reducing the incidence of flea allergy dermatitis (FAD) in a companion animal are disclosed, the methods directed to inhibiting blood feeding by ectoparasites on a companion animal. The methods of the present invention involve administering a pesticide composition comprising cyphenothrin to a companion animal, specifically dogs and cats, in doses and proportions which are parasiticidally effective against a variety of ectoparasites, and in formulations which are convenient for topical application to the animal's skin, preferably localized over a small surface area. Such methods are useful in preventing and/or reducing the incidence of flea allergy dermatitis.
Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
Type:
Grant
Filed:
January 12, 2009
Date of Patent:
December 10, 2013
Assignees:
Centre National de Recherche Scientifique, Institut Curie, Universite Montpellier 2 sciences et Techniques
Inventors:
Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
Type:
Grant
Filed:
October 12, 2012
Date of Patent:
December 10, 2013
Assignee:
Hoffman-La Roche Inc.
Inventors:
Pascal Dott, Steven Paul Hanlon, Stefan Hildbrand, Hans Iding, Andrew Thomas, Pius Waldmeier
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Type:
Grant
Filed:
December 6, 2011
Date of Patent:
November 26, 2013
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
Abstract: Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.
Type:
Grant
Filed:
April 27, 2011
Date of Patent:
November 19, 2013
Assignee:
Massachusetts Institute of Technology
Inventors:
Barbara Imperiali, Elvedin Lukovic, Dora Carrico-Moniz
Abstract: Substituted nicotinamides, processes for their preparation, medicaments comprising these compounds and methods of using these compounds to treat pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, and/or dystonia-associated dyskinesias.
Type:
Grant
Filed:
March 30, 2012
Date of Patent:
November 19, 2013
Assignee:
Grünenthal GmbH
Inventors:
Sven Kühnert, Beatrix Merla, Gregor Bahrenberg, Wolfgang Schröder
Abstract: The described invention provides a gel formulation of a composition comprising at least one insecticide in an amount effective to control an insect larval population, an apparatus for autodissmenination of an insecticide for insect management containing (1) a cap component, (2) a cup component, and (3) a mesh component, a method and a system for autodissemination for effectively controlling an insect larval population. Also disclosed is an improvided biphasic autodissemination station for control of undesirable insect populations.
Abstract: The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The present invention also discloses the use of the compound with general formula (I) as an insecticide in the agricultural field and an insecticidal composition using the compound with general formula (I) as an active component.
Type:
Application
Filed:
March 28, 2012
Publication date:
November 14, 2013
Applicants:
Shenyang Research Institute Of Chemical Industry Co., Ltd., SINOCHEM CORPORATION
Abstract: The present invention provides compounds of Formula below: and analogues thereof where the various substituent groups, R1, R2, R3, R4, R5 A, and X are described herein; or a pharmaceutical salt thereof; a method of treating a condition such as hypertriglyceridemia and a process for preparing the compounds.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
November 5, 2013
Assignee:
Eli Lilly and Company
Inventors:
Maria Carmen Fernandez, Lance Allen Pfeifer, Maria Rosario Gonzalez-Garcia
Abstract: An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness.
Abstract: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: one or more fixing polymer(s) (i), one or more associative polymer(s) (ii) different from the fixing polymer(s), one or more antidandruff agent(s) (iii), and to a process using this composition, and to the use thereof.
Abstract: There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof.
Abstract: Dual action lethal containers, systems, methods, compositions and formulas used to kill mosquitoes and their larvae. The containers can have separate interior larvicidal and adulticidal coatings separated from each other by horizontal water line holes in the container. Another container can use a novel combined coating of a larvicidal and adulticidal coating. Unique compositions of adulticidal coatings, larvicidal coatings and combined adulticidal and larvicidal coatings can be used as liners.
Type:
Application
Filed:
April 19, 2013
Publication date:
October 24, 2013
Applicant:
University of Florida Research Foundation, Inc.
Inventors:
Philip G. Koehler, Ephraim V. Ragasa, Roberto M. Pereira
Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
Type:
Application
Filed:
October 18, 2011
Publication date:
October 24, 2013
Applicant:
ELCELYX THERAPEUTICS, INC.
Inventors:
Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
Abstract: MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.
Type:
Grant
Filed:
March 9, 2010
Date of Patent:
October 22, 2013
Assignee:
Bristol-Myers Squibb Company
Inventors:
Saleem Ahmad, William N. Washburn, Andres S. Hernandez, Jeffrey A. Robl, Khehyong Ngu, Zhenghua Wang
Abstract: A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of Formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants.
Type:
Grant
Filed:
April 23, 2008
Date of Patent:
October 8, 2013
Assignee:
Syngenta Crop Protection LLC
Inventors:
Hans Tobler, Harald Walter, Ulrich Johannes Haas
Abstract: A formulation and method for insect control is provided in the form of insecticide carrying insects which can be introduced in a population to thereby control the insect population. The formulation may include artificially generated adult insect carriers of a larvicide in which the larvicide has minimal impact on the adult insect and which larvicide affects juvenile survival or interferes with metamorphosis of juvenile insects to adulthood. The insects may be either male or female and may include mosquitoes.
Abstract: The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with ?-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits ?-secretase activity. The subject invention also provides methods to increase ?-secretase expression and/or activity in cells by administering polyphenol flavonoids like (?)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of A?1-40 or A?1-42 by administering the EGCG and EC compounds, their analogs, metabolites, and prodrugs.
Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.
Type:
Grant
Filed:
February 20, 2012
Date of Patent:
September 24, 2013
Assignees:
Pfizer Limited, Icagen, Inc.
Inventors:
Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
Type:
Application
Filed:
May 17, 2013
Publication date:
September 19, 2013
Applicant:
FibroGen, Inc.
Inventors:
Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
Abstract: The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.
Type:
Application
Filed:
May 14, 2013
Publication date:
September 19, 2013
Applicant:
CELL THERAPY AND TECHNOLOGY, S.A. DE C.V.
Inventors:
José Agustín Rogelio MAGAÑA CASTRO, Laura VÁZQUEZ CERVANTES, Juan Socorro ARMENDÁRIZ BORUNDA
Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
Abstract: The present invention relates to a cyanoacrylate-based bio-adhesive composition, and aims to provide a cyanoacrylate-based bio-adhesive composition having an excellent biodegradability and anti-bacterial effect. The present invention provides a cyanoacrylate-based bio-adhesive composition having an enhanced biodegradability by using, as a thickening agent, poly octyl cyanoacrylate generated as a byproduct when preparing octyl cyanoacrylate, and having an excellent anti-bacterial effect by using 3,5-diiodo-4-pyridone-1-acetic acid as an anion stabilizer.
Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Abstract: A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.
Type:
Grant
Filed:
September 26, 2011
Date of Patent:
August 27, 2013
Assignee:
Intermune, Inc.
Inventors:
Ramachandran Radhakrishnan, Michael Cyr, Sabine M. Pyles
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Application
Filed:
March 21, 2013
Publication date:
August 22, 2013
Applicants:
The Regents of the University of California, Otonomy, Inc.
Inventors:
Otonomy, Inc., The Regents of the University of California
Abstract: Compound of Formula (I): wherein R1, R2 and R3, which are identical or different, are hydrogen atom or C1-4 alkyl, and R4 is a saturated C6-9 linear, branched or cyclic hydrocarbon radical or a radical of Formula (II) wherein X is S or O, Y is a hydrogen atom or up to 2 halogen atoms, Z is a single bond or a divalent radical being O, S, —CR2—, in which R is hydrogen or C1-4 alkyl, or other divalent radical with 2-10 carbon atoms and, optionally, O and/or S atoms linked in the form of a chain, wherein—if the radicals contain 2 or more O and/or S atoms—the latter are separated from one another by at least 2 carbon atoms, and it also being possible for 2 adjacent carbon atoms to be linked together by a double bond, and the free valencies of the carbon atoms being saturated by a hydrogen atom and/or C1-4 alkyl groups, Ar is an aromatic ring system which has up to two rings and which may be substituted by up to three radicals from the group of fluorine, chlorine, bromine, methoxy, C1-4 alkyl, trifluoromethyl and t
Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).
Type:
Application
Filed:
July 1, 2011
Publication date:
August 8, 2013
Applicant:
GILEAD SCIENCES, INC.
Inventors:
Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.
Type:
Grant
Filed:
May 29, 2010
Date of Patent:
August 6, 2013
Assignee:
University of Florida Research Foundation
Abstract: Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) in which A, R1, R2 and R3 are as defined in the description, and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.
Abstract: Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.
Type:
Application
Filed:
November 5, 2010
Publication date:
July 25, 2013
Applicant:
The Trustees of Columbia University in the City of New York
Abstract: The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.
Type:
Grant
Filed:
August 14, 2008
Date of Patent:
July 23, 2013
Assignee:
Cell Therapy and Technology, S.A. De C.V.
Inventors:
José Agustín Rogelio Magaña Castro, Laura Vázquez Cervantes, Juan Socorro Armendáriz Borunda
Abstract: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.
Type:
Grant
Filed:
January 14, 2008
Date of Patent:
July 16, 2013
Assignee:
Foamix Ltd.
Inventors:
Dov Tamarkin, Meir Eini, Doron Friedman, Alex Besonov, David Schuz, Tal Berman, Jorge Danziger, Rita Keynan, Ella Zlatkis